Shukra Pharmaceuticals Limited equity shares have been listed and admitted to dealings on the National Stock Exchange of India Limited effective August 14, 2026. The listing marks a dual-listing milestone for the pharma firm, which continues to trade on the Bombay Stock Exchange. The move aims to enhance liquidity and expand the investor base.

The company marked this landmark milestone with the iconic ceremonial opening bell ringing at the NSE Exchange Plaza in Mumbai on Friday, August 14, 2026. This transition to the NSE represents a direct listing from the BSE, where the company's shares will continue to trade actively. The dual-listing strategy is aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.

The trading details for the equity shares on the NSE are as follows:

The base reference price for the initial trading session on the NSE was determined based on the closing market price of the shares on the BSE on August 13, 2026. Shukra Pharmaceuticals disclosed this development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dakshesh Shah, Managing Director of Shukra Pharmaceuticals, stated that the listing reflects the company's strong financial health and operational scaling. He noted that trading on the NSE expands reach to institutional investors and increases market liquidity, moving the company closer to its goal of becoming a premier name in global pharmaceutical manufacturing. Shah added that the direct listing is a testament to transparent corporate governance and shareholder trust.

Shivkant Dhakad, Company Secretary and Compliance Officer of Shukra Pharmaceuticals, confirmed the commencement of trading. The company requested the exchanges to disseminate the information for the benefit of investors and the public. The company confirms that all relevant corporate disclosures, historical operational metrics, and the latest financial results have been filed uniformly under the SEBI regulations across both exchanges to prevent information asymmetry.

Shukra Pharmaceuticals reported a substantial turnaround in profitability for the first quarter of FY26, with standalone net profit rising to ₹1,502.98 lakh compared to ₹102.96 lakh in the corresponding period of FY25. The surge was underpinned by a 336% year-on-year increase in revenue from operations, which reached ₹2,352.23 lakh against ₹539.11 lakh in Q1FY25. This performance marks a sharp recovery from the net loss of ₹172.67 lakh reported in the preceding quarter (Q4FY25), signaling improved operational efficiency and demand for its pharmaceutical products.

The Board of Directors approved the unaudited financial results at a meeting held on August 12, 2026, at the company’s registered office in Ahmedabad. The results were reviewed by the Audit Committee and subjected to a limited review by M/s Shah Sanghvi and Associates, Chartered Accountants, the statutory auditors of the company. The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) 34 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Consolidated net profit for the quarter stood at ₹1,295.85 lakh, compared to ₹102.96 lakh in Q1FY25. Consolidated revenue from operations remained consistent with standalone figures at ₹2,352.23 lakh. The consolidated segment information reveals that the pharmaceutical segment generated a pre-tax and pre-interest profit of ₹1,860.13 lakh, while the MedTech segment, effective from October 1, 2025, contributed no revenue or profit in this period.

What the Numbers Show

The most striking aspect of the Q1FY26 results is the dramatic improvement in operating leverage. While revenue surged by over three times compared to the prior year, total expenses decreased significantly to ₹381.97 lakh from ₹512.78 lakh in Q1FY25. This divergence suggests a major shift in cost structure or inventory management, evidenced by a change in inventory valuation of (₹279.00 lakh) versus a positive ₹201.88 lakh in the previous year. Additionally, finance costs increased modestly to ₹42.95 lakh from ₹26.81 lakh, but this was more than offset by the expansion in top-line growth, resulting in a profit before tax of ₹2,024.23 lakh, up from ₹137.30 lakh in Q1FY25.

The company operates in two segments: Shukra Pharmaceutical and Shukra MedTech. The pharmaceutical segment remains the primary driver of value, accounting for all reported revenue and the majority of segment assets. No investor complaints were received during the quarter ended June 30, 2026, indicating stable stakeholder relations. The paid-up equity share capital remained unchanged at ₹4,378.79 lakh.